Barbara Scarpa, APRN
Adult Health · Oxford, CTNPI 1811565237
Payments from drug & device makers
Across 80 payments — averaging $24.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$602
- Novo Nordisk$305
- Viiv Healthcare Company$278
- AstraZeneca$157
- Pfizer$151
- Optinose US, Inc.$91
- plus $354 from 10 others
What the payments were for
- Food & beverage$1,937100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 28 | $602 |
| Novo Nordisk | 11 | $305 |
| Viiv Healthcare Company | 3 | $278 |
| AstraZeneca | 8 | $157 |
| Pfizer | 8 | $151 |
| Optinose US, Inc. | 4 | $91 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $64 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $63 |
| Intra-sana Laboratories | 2 | $39 |
| Sunovion Pharmaceuticals Inc. | 4 | $34 |
| Exact Sciences | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $26 |
| Lilly USA, LLC | 1 | $26 |
| GSK | 1 | $25 |
| Merck | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,937 in reported general payments places this provider in the 75th percentile of 418 adult health providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 34 | $48,926 |
| EliquisApixaban | 29 | $36,484 |
| GemtesaVibegron | 29 | $24,913 |
| OzempicSemaglutide | 23 | $22,766 |
| JanuviaSitagliptin Phosphate | 15 | $19,266 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $14,893 |
| JardianceEmpagliflozin | 13 | $14,789 |
| MyrbetriqMirabegron | 11 | $11,726 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $6,182 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 32 | $5,054 |
| Colchicine | 17 | $2,656 |
| Levothyroxine Sodium | 242 | $2,344 |
| Rosuvastatin Calcium | 214 | $2,198 |
| Metoprolol Succinate | 107 | $2,060 |
| Atorvastatin Calcium | 280 | $1,957 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $157 | $48,92634 claims |
| PfizerEliquis | $151 | $36,48429 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $26 | $24,91329 claims |
| Novo NordiskOzempic | $305 | $22,76623 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $25 | $21,07535 claims |
| MerckJanuvia | $23 | $19,26615 claims |
| AbbVieSynthroid | $602 | $1,65330 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 418 adult health providers in Connecticut.
Other adult health in Oxford
- Leah EhleManchester$418K
- Laura MulkaWethersfield$306K
- Gretchen MichaelsonSouth Windsor$169K
- Kimberly RyanWethersfield$74K
- Kathryn JackMeriden$67K
- Lynn RapsilberTorrington$52K
- Genice NelsonFarmington$36K
- Andrea LauterNew London$32K
- Megan CarlucciManchester$28K
- Kellie HaleNew Haven$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.